Tc-99m-Pertechnetate-Avid Metastases From Differentiated Thyroid Cancer Are Prone To Benefit From I-131 Therapy A Prospective Observational Studyprospective Observational Study

Min Liu,Li Chai,Qiong Luo,Maomei Ruan,Lingxiao Cheng,Zhongwei Lv,Libo Chen

DOI: https://doi.org/10.1097/MD.0000000000007631

IF: 1.6

2017-01-01

Medicine

Abstract:The aim of this study is to determine the contribution of neck and chest Tc-99m-pertechnetate scan to the management of postoperative patients with suspicious metastatic differentiated thyroid cancer (DTC), particularly to the prediction of response to radioiodine (I-131) therapy. Just before 131I administration, a total of 184 postoperative DTC patients with stimulated serum thyroglobulin (ssTg)>10ng/mL were enrolled to undergo neck and chest Tc-99m-pertechnetate scan, which were directly compared with post-therapeutic 131I scan to determine the concordance of site and number of metastatic lesions. The percentage changes in ssTg between Tc-99m-pertechnetateavid group and Tc-99m-pertechnetate- nonavid groupwere compared, and the response to(131)I inboth groupswasanalyzed according to the nature of Tc-99m-pertechnetateavidity as well. The percentages of concordance between Tc-99m-pertechnetate and I-131 scan in detecting metastases were 65.7% and 26.0% in per-patient and per-site analyses with low unweighted kappa, respectively. (99m)Tcpertechnetate scan led to a change in therapeutic decision making in 19/184 (10.3%) patients. In 72 patients with 131I-avid metastases, the ssTg in Tc-99m-pertechnetate-avid group (n= 13) decreased significantly compared with that in Tc-99m-pertechnetate-nonavid group (n= 59) (median: -81.56% vs -48.14%; Z= -4.276, P=.000). The difference of therapeutic response between 99mTc-pertechnetateavid group and Tc-99m-pertechnetate-nonavid group was statistically significant (x(2)=8.4; P=.03). Although the consistency between Tc-99m-pertechnetate scan before I-131 administration and post-therapy I-131 scan in detecting metastases is low, identifying metastases in postoperative DTC patients with elevated ssTg via Tc-99m-pertechnetate scan prior to I-131 therapy provides incremental value for therapeutic decision making. Notably, patients with Tc-99m-pertechnetate-avid metastases may be more prone to benefit from I-131 therapy than those with Tc-99m-pertechnetate-nonavid metastases.